Proteomic Profiles to Provide Predictors of Drug-Modulated Targets and Responses

Proteomic profiles to provide predictors of drug-modulated targets and responses 

Individuals with inherited familial adenomatous polyposis (FAP) develop numerous polyps, the premalignant precursors to colorectal carcinoma. A remarkable heterogeneity in patient response was observed in a clinical trial with a cyclooxygenase-2-inhibitor, celocoxib, which is known to be efficacious in FAP. SELDl proteomic profile revealed that a putative marker at 16,961.4 Da was a strong discriminator between response and nonresponse [134]. 

---